506690 Stock Overview A pharmaceutical company, manufactures and sells pharmaceutical products worldwide. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Unichem Laboratories Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Unichem Laboratories Historical stock prices Current Share Price ₹726.85 52 Week High ₹949.85 52 Week Low ₹429.95 Beta 0.16 1 Month Change -12.98% 3 Month Change 14.45% 1 Year Change 60.77% 3 Year Change 173.82% 5 Year Change 342.12% Change since IPO 419.18%
Recent News & Updates
Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024) Nov 14
Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Oct 25
Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 26
High number of new directors Jul 17
Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023) Jul 12
Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024 Jun 29 See more updates
Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024) Nov 14
Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Oct 25
Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 26
High number of new directors Jul 17
Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023) Jul 12
Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024 Jun 29 Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd Jun 06
Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024 May 31
Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023) May 23
Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024 May 11
Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023) Feb 06
Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024 Jan 16
Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg Jan 12
Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023) Nov 02
Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023 Oct 19
Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023 Aug 22
Insider recently sold ₹12m worth of stock Aug 19
Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors Aug 10
Insider recently sold ₹1.5m worth of stock Jul 24
First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023) Jul 15
Non-Executive Independent Director recently sold ₹10m worth of stock Jun 02
Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022) May 24
Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022) Feb 07
Krka Reportedly Eyes Promoter Stake in Unichem Laboratories Jan 31
Insufficient new directors Nov 16
Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022) Nov 13
Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 04
Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration Oct 15
Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP Aug 23
Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets Aug 18
Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration Aug 10
Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022 Aug 03
Upcoming dividend of ₹4.00 per share Jul 25
Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021) Jul 14
Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022 Jun 29
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 29
Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022 May 28
Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022 May 20
Insufficient new directors Apr 27
Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet Mar 01
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Jan 30
Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021) Nov 07
Upcoming dividend of ₹4.00 per share Jul 15
Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020) Jul 06
Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets Jul 03
Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020) May 30
Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021 May 30
Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg May 21
Insider recently bought ₹2.3m worth of stock Apr 04
Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration Mar 05
New 90-day high: ₹332 Feb 25
Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration Feb 19
New 90-day high: ₹294 Feb 02
Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020) Feb 01
Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA Jan 28
Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021 Jan 22
New 90-day high: ₹286 Jan 15
Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg Jan 14
New 90-day high: ₹285 Dec 07
Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet Nov 29
New 90-day low: ₹237 Nov 06
Second quarter 2021 earnings released: EPS ₹1.24 Nov 04
First half earnings released Nov 01
Upcoming Dividend of ₹4.00 Per Share Aug 13
First quarter earnings released Aug 05
New 90-day high - ₹214 Jul 30 Shareholder Returns 506690 IN Pharmaceuticals IN Market 7D 4.6% 3.1% 0.5% 1Y 60.8% 36.2% 17.4%
See full shareholder returns
Return vs Market: 506690 exceeded the Indian Market which returned 17.4% over the past year.
Price Volatility Is 506690's price volatile compared to industry and market? 506690 volatility 506690 Average Weekly Movement 6.7% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 506690 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 506690's weekly volatility (7%) has been stable over the past year.
About the Company Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services.
Show more Unichem Laboratories Limited Fundamentals Summary How do Unichem Laboratories's earnings and revenue compare to its market cap? 506690 fundamental statistics Market cap ₹51.17b Earnings (TTM ) -₹55.64m Revenue (TTM ) ₹17.75b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 506690 income statement (TTM ) Revenue ₹17.75b Cost of Revenue ₹7.27b Gross Profit ₹10.48b Other Expenses ₹10.54b Earnings -₹55.64m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.79 Gross Margin 59.06% Net Profit Margin -0.31% Debt/Equity Ratio 11.2%
How did 506690 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 00:43 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Unichem Laboratories Limited is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Rakesh Nayudu Almondz Global Securities Ltd Sriraam Rathi Anand Rathi Shares and Stock Brokers Limited null null Anand Rathi Shares and Stock Brokers Limited
Show 10 more analysts 
